Kintara Therapeutics Management
Management criteria checks 3/4
Kintara Therapeutics' CEO is Robert Hoffman, appointed in Nov 2021, has a tenure of 2.5 years. total yearly compensation is $1.18M, comprised of 49.8% salary and 50.2% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth $481.83. The average tenure of the management team and the board of directors is 3.8 years and 3.9 years respectively.
Key information
Robert Hoffman
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 49.8% |
| CEO tenure | 2.5yrs |
| CEO ownership | 0.006% |
| Management average tenure | 3.8yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Kintara soars 66% on pausing breast cancer study, to use cash for brain cancer trial
Oct 19Kintara Therapeutics GAAP EPS of -$0.52
Sep 27Kintara Therapeutics rallies after $20M stock purchase deal with Lincoln Park Capital Fund
Aug 03Kintara Therapeutics (NASDAQ:KTRA) Will Have To Spend Its Cash Wisely
Apr 12
Kintara Therapeutics shares rise on mid-stage glioblastoma trial update
May 26Kintara initiates recruitment for VAL-083's study arm in the GBM AGILE trial
Jan 13Kintara Therapeutics reports VAL-083 interim data for the treatment of glioblastoma multiforme
Nov 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$11m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | US$1m | US$590k | -US$15m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | n/a | n/a | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$22m |
| Jun 30 2022 | US$3m | US$357k | -US$25m |
| Mar 31 2022 | n/a | n/a | -US$26m |
| Dec 31 2021 | n/a | n/a | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | US$270k | n/a | -US$42m |
| Mar 31 2021 | n/a | n/a | -US$39m |
| Dec 31 2020 | n/a | n/a | -US$34m |
| Sep 30 2020 | n/a | n/a | -US$30m |
| Jun 30 2020 | US$113k | n/a | -US$9m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | n/a | n/a | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | US$70k | n/a | -US$8m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | n/a | n/a | -US$9m |
| Sep 30 2018 | n/a | n/a | -US$11m |
| Jun 30 2018 | US$151k | n/a | -US$11m |
Compensation vs Market: Robert's total compensation ($USD1.18M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.
CEO
Robert Hoffman (57 yo)
2.5yrs
Tenure
US$1,184,363
Compensation
Mr. Robert E. Hoffman, BBA, CPA, serves as an Independent Director at FibroBiologics, Inc. (Formerly, FibroBiologics LLC) since April 2021. He had been Independent Director of Antibe Therapeutics Inc. sinc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.5yrs | US$1.18m | 0.0056% $ 481.8 | |
| Founder | 14.3yrs | no data | no data | |
| Acting Head of Operations | 3.8yrs | no data | no data |
3.8yrs
Average Tenure
Experienced Management: KTRA's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.1yrs | US$1.18m | 0.0056% $ 481.8 | |
| Independent Director | 3.1yrs | US$83.44k | 0% $ 0 | |
| Independent Director | 10.8yrs | US$80.94k | 0.000060% $ 5.2 | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data | |
| Independent Director | 3.9yrs | US$79.94k | 0.00011% $ 9.4 |
3.9yrs
Average Tenure
59yo
Average Age
Experienced Board: KTRA's board of directors are considered experienced (3.9 years average tenure).